Novavax COVID vaccine hits 90 per cent efficacy in late-stage trial; shares leap

Novavax COVID vaccine hits 90 per cent efficacy in late-stage trial; shares leap
Novavax (NVAX) said Monday that its developing coronavirus vaccine passed a 90 per cent efficacy rate in late-stage trials and said it plans to seek regulatory approval in the coming months.

Novavax said its NVX-CoV2373 coronavirus vaccine candidate hit a 90.4 per cent efficacy rate in a trial of nearly 30,000 participants, with a 100 per cent protection rate against moderate and severe forms of the disease. Its efficacy rate against ‘predominantly circulating’ variants, Novavax said, was around 93 per cent.

The Gaithersburg, Maryland-based drugmaker said it expects to seek regulatory approval for the vaccine in the third quarter, and remains on track to reach manufacturing capacity of 100 million doses per month by October and 150 million does per month by the end of the year.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,” said CEO Stanley Erck. “Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”

Novavax shares were marked 11.1 per cent higher in pre-market trading Monday following news of the trial to indicate an opening bell price of $233.00 each.

Last week, Moderna MRNA formally asked the U.S. Food & Drug Administration for emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.

Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study “met its primary immunogenicity end point, successfully bridging immune responses to the adult vaccination’ with a vaccination efficacy of 100 per cent among the 2,500 participants. A 93 per cent efficacy rate was also noted 14 days after the first of the vaccine’s two dose regiment, Moderna said.
Read more on Toronto Star
News Topics :
Similar Articles :
Novavax NVAX shares edged higher on Thursday after the company’s COVID 19 vaccine candidate showed high efficacy rates against both the original strain of the virus as well as the Alpha...
Top Stories
WASHINGTON, UNITED STATES US biotech firm Novavax on Monday said it had positive results from preclinical studies of a shot combining its influenza and COVID vaccine candidates....
The small biotech firm Novavax, once considered a dark horse in the COVID 19 vaccine race, announced today that its candidate delivered high efficacy89.3 in a pivotal trial in the United Kingdom...
The dark horse vaccine company Novavax announced strong results today from a pivotal, 30, 000 person trial of its pandemic coronavirus vaccine in the United States and Mexico. The vaccine uses a...
Lordstown Motors RIDE was falling after the electric truck maker said Chief Executive Steve Burns would step down following an independent investigation into allegations made by short seller Hindenburg Research that called...